Loading clinical trials...
Loading clinical trials...
Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma Who Refused Chemotherapy: an Open, Single-arm, Single-center Clinical Trial
Conditions
Interventions
Anlotinib
Start Date
November 1, 2018
Primary Completion Date
November 1, 2019
Completion Date
November 1, 2020
Last Updated
November 2, 2018
NCT07336732
NCT05568212
NCT06574347
NCT02448992
NCT06281964
NCT05904379
Lead Sponsor
First Affiliated Hospital of Wenzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions